Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Quarter Earnings Dampened By Severe Weather

This article was originally published in The Pink Sheet Daily

Executive Summary

Keryx cautions investors that a Zerenex approval is not guaranteed; NPS reports sluggish Gattex sales; Eylea sales down, but expected to rebound with new indications in the second half; Ariad’s Iclusig relaunch off to a good start.

You may also be interested in...



Regeneron Touts Potential Of Growing Eylea Franchise After Robust Q4

Speaking at the J.P. Morgan meeting in January, Regeneron CEO Leonard Schleifer says the company is exploring many opportunities to build the franchise around its successful wet AMD drug Eylea. In the fourth quarter, the drug racked up $400 million in U.S. sales, beating expectations.

Zerenex To Be Positioned As Cost-Saving, Oral Alternative In ESRD Setting

Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel